

2022 FNIH Biomarkers Consortium Cancer Steering Committee Virtual Symposium Agenda

DAY 1: October 27, 2022, 1:00 – 4:30 pm ET

1:00 – 1:15 Introductions and Housekeeping: Dana Connors, MSc, FNIH

1:15 – 1:35 Welcome: Gary Kelloff, MD, NCI

1:35 – 2:10 Keynote: James Heath, PhD, Institute for Systems Biology

SESSION 1: Biomarkers from Real World and Other Big Data

2:10 – 2:45 Wearable Technology, Remote Sensors, and Patient Monitoring

Moderator: Mike Espey, PhD, NCI

Talk: Using Data from Wearables and Remote Sensors to Define Biomarkers for Patient Selection and Treatment Monitoring

Chris Hartshorn, PhD, National Center for Advancing Translational Science (NCATS)

Panel: Wearable Technology, Remote Sensors, and Patient Monitoring

Chris Hartshorn, PhD, NCATS

Karen Mustian, Ph.D., M.P.H., University of Rochester

Steven Hoffmann, MSc, FNIH

2:45 – 3:20 Predicting Patient Outcomes Using Clinical Trial Data

Moderator: Andrew Lo, PhD, MIT

Talk: Can Data Science Help Cure Cancer?

Andrew Lo, PhD, MIT

Panel: Using Data from Multiple Clinical Trials to Predict Patient Outcomes

Tito Fojo, PhD, Columbia University

Nick Kelley, Chief Digital Office, Novartis

Sean Khozin, former CEO, CancerLinQ

3:20 – 3:25 BREAK

3:25 – 4:00 Genome-Wide Identification and Analysis of Prognostic Features in Humans

Moderator: Vincent Miller, MD, EQRX

Talk: Genome-Wide Identification and Analysis of Prognostic Features in Humans

Jason M. Sheltzer, PhD, Yale University School of Medicine

Panel: Using Data from Well-Curated “Public” Resources to Create Complex Biomarkers

Lynda Chin, PhD, Apricity Health

Tracy Lively, PhD, NCI

Soma Ghosh, PhD, FDA

Bill Louv, PhD, Project Data Sphere

Sean Hanlon, PhD, NCI

Jason M. Sheltzer, PhD, Yale University

4:00 – 4:30 Panel: Public-Private Partnerships in Support of Next-Generation Biomarker Development

Moderator: Sean Khozin, MD, MPH, formerly CancerLinQ

Andrew Lo, PhD, MIT

Reena Philip, PhD, FDA

Joshua Ofman, MD, MSHS, GRAIL Bio

2022 FNIH Biomarkers Consortium Cancer Steering Committee Virtual Symposium Agenda

DAY 2: October 28, 2022, 1:00 – 4:00 pm ET

1:00 – 1:10 Introductions, Housekeeping Welcome: Geoff Oxnard, MD, Foundation Medicine

1:10 – 1:45 Keynote: J. Carl Barrett, PhD, Astra Zeneca

SESSION 2: Clinical Utility of Complex Digital Pathology and Liquid Biopsy Biomarkers

1:45 – 2:35 Digital Pathology

Moderator: Stan Hamilton, MD, City of Hope

Talk: Digital Pathology: State of the Science

Liron Pantanowitz, MD, MHA, University of Michigan, Ann Arbor

Panel: Clinical Application of Digital Pathology

Marilyn M. Bui, MD, PhD, Moffitt Cancer Center

Anil Parwani, MD, PhD, MBA, The Ohio State University

Mike Espey, PhD, NCI

Peter Sorger, Harvard Medical School

2:35 – 2:50 Break

2:50 – 3:25 Translating Liquid Biopsy into the Clinic

Moderator: Minetta Liu, MD, Natera

Talk: Defining Clinical Utility of a Tumor Biomarker Test or When Should a Tumor Biomarker Be Applied in the Clinic?

Daniel F. Hayes, MD, FASCO, FACP

Talk: Making Liquid Biopsy Reference Materials “Fit for Purpose”

Jerry Radich, MD, Fred Hutchinson Cancer Center

Breakout Panel: Enabling Real World Applications for the Liquid Biopsy

David Gandara, MD, UC Davis, ISLB

Amy Moore, PhD, Lungevity

Soma Ghosh, PhD, FDA

Jerry Radich, MD, Fred Hutchinson Cancer Center

Daniel F. Hayes, MD, University of Michigan

3:25 – 3:55 Panel: Clinical Implementation and the Role of Public-Private Partnership

Moderator: Geoff Oxnard, MD, Foundation Medicine

Esther Abels, MSc, Precision Medicine | BioMedical Regulatory Health Science Expert

Stan Hamilton, MD, City of Hope

Francisca Reyes Turcu, PhD, FDA

Minetta Liu, MD, Natera

David Rimm, MD, PhD, Yale

Geoff Oxnard, MD, Foundation Medicine

2022 FNIH Biomarkers Consortium Cancer Steering Committee Virtual Symposium Agenda

DAY 3: November 3, 2022, 1:00 – 4:30 pm ET

1:00 – 1:10 Introductions, Housekeeping, Welcome: Emmett Schmidt, MD, PhD, Merck

1:10 – 1:40 Keynote: Marc Theoret, MD, FDA

SESSION 3: Applying Knowledge Across the Disease Continuum

1:40 – 2:30 Immune Microenvironments

Moderator: Lanny Kirsch, MD, Adaptive Technologies

Special Keynote: Steve Rosenberg, MD, PhD, NCI

Breakout Panel: The TME, the ME, and the E

Michael Khodadoust, MD, PhD, Stanford

Alex Snyder, MD, Generate Biomedicines, SITC

Jerry Radich, MD, Fred Hutchinson Cancer Center

2:30 – 3:05 Imaging

Moderator: Dan Sullivan, MD, Duke

Talk: Challenges and Opportunities for Imaging Immunity

Umar Mahmood, MD, PhD, Massachusetts General Hospital, Harvard Medical School

Panel: Novel Imaging Techniques

Gregory Goldmacher, MD, PhD, MBA, Merck

John Waterton, PhD, Univ. of Manchester, UK; Bioxydyn

Nola Hylton, PhD, UCSF

Wolfgang Weber, MD, Technical University of Munich

3:05 – 3:20 BREAK

3:20 – 3:55 Applying Knowledge from Other Therapeutic Areas

Moderator: Hartmuth Kolb, PhD, Janssen

Panel: The Potential for Cross-Disease Application of Tools

Eric Hostetler, PhD, Merck

Marty Pomper, MD, PhD, Johns Hopkins

Umar Mahmood, MD, PhD, Mass. Gen. Hospital, Harvard

Gary Ulaner, MD, PhD, Hoag

Session 4: Platform Trials: Challenges and Opportunities

Moderator: Laura Esserman, MD, MBA, UCSF

3:55 – 4:35 Panel

Experience with Changes in the Standard of Care Over Time

Donald Berry, PhD, Berry Consultants (I-SPY)

Hossein Borghaei, DO, MS, Fox-Chase (Lung-MAP)

Power to Advance Molecular and Imaging Biomarkers

Laura van't Veer, PhD, UCSF

Diversity, Equity, and the Role of Advocacy

Jane Perlmutter, PhD, MBA, Gemini Group

2022 FNIH Biomarkers Consortium Cancer Steering Committee Virtual Symposium Agenda

DAY 4: November 4, 2022, 1:00 – 4:00 pm ET

1 – 1:15 Introductions and Housekeeping: Gary Kelloff, MD, NCI

1:15 – 2:00 Keynote: Doug Lowy, MD, NCI

SESSION 5: Expanding Early Diagnostics Into Early Detection & Cancer Prevention/Interception

Moderator: Ernest Hawk, MD, MPH, UT MD Anderson Cancer Center

Talk: Resources of the NCI/DCP and the Early Detection Research Network

Sudhir Srivastava, PhD, MPH, NCI

Talk: Industry's Perspectives on Multicancer Early Detection Test Development

Paul Limburg, MD, MPH, Exact Sciences

2:30 – 2:45 BREAK

Talk: Integrating Cancer Risk Assessment & Prevention/Interception in High-Risk Cohorts

Eduardo Vilar-Sanchez, MD, PhD, UT MD Anderson

Talk: Advancing Early Cancer Detection via MCEds into Clinical Practice – What Questions Need Answers?

Ernest Hawk, MD, MPH, UT MD Anderson Cancer Center

Panel: Near-Term Prospects for MCEds to Advance Cancer Early Detection & Interception

Danielle Krol, MD, FDA

Ruth Etzioni, PhD, Fred Hutchinson

Peter Bach, MD, DELFI Diagnostics

3:45 – 4:00 Concluding Remarks